In June 2023, RheumNow surveyed US and non-US rheumatologists (Rheums) about how they consider and manage pre-clinical rheumatoid arthritis (RA) in their practice.Read Article
What’s your next best approach to the rheumatoid arthritis (RA) patient who has failed several DMARDs and biologics? In such cases you have to either reconsider the diagnosis (especially if seronegative) or reach into your bag of tricks.Read Article
Dr. Jack Cush is joined by Dr. Michael Weinblatt as they discuss this weeks news and journal reports, including difficult RA, HLA typing and abatacept responses and new regulatory decisions.Read Article
In a recent randomized clinical trial of patients with fibromyalgia, cognitive-behavioral therapy (CBT)—which uses structured techniques to alter distorted thoughts and negative moods—was superior to a matched education treatment in reducing the interfering effects of pain and other aspects of fiRead Article
The FDA quietly approved the interleukin (IL)-1 inhibitor canakinumab (Ilaris) for gout 10 days ago, with no announcement from either the agency or the drug's manufacturer, Novartis -- leaving outsiders to guess at what changed in the dozen years since the company's first attempt to gain approvalRead Article
We use biologic agents on a daily basis in the treatment of rheumatoid arthritis. Despite having an expanding array of options, our profession is keen on gaining a deeper understanding of why certain drugs fail and being able to predict the most appropriate next steps in treatment.Read Article
A machine learning approach was applied to two different population cohorts and was shown to be effective at the early identification of undiagnosed psoriatic arthritis (PsA).Read Article
This week, Dr. Jack Cush reviews the news with special guest, Dr. Peter Nash. They discuss COVID Autoantibodies, SpA life expectancy, HCQ, extraarticular RA and our approach to Early RA referrals and pre-clinical RA.Read Article
This Tuesday Night Rheumatology was an hour long panel discussion featuring Drs. Jack Cush, Vivian Bykerk, Glen Hazelwood and Martin J. Bergman.
The Panel discussed Rheumatologists views on Early RA referral and intake, initial treatment preferences and views on diagnosing and treating pre-clinical RA.
Daily hydroxychloroquine (HCQ) is better than an apple a day; as a new study shows that adherence to the antimalarial agent significantly lowers future risk of cardiovascular events in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) patients.Read Article